Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Leap Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
LPTX
Nasdaq
2836
www.leaptx.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Leap Therapeutics, Inc.
Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study
- Jan 28th, 2025 12:00 pm
Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference
- Jan 6th, 2025 12:00 pm
Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference
- Nov 26th, 2024 12:00 pm
Leap Therapeutics Reports Third Quarter 2024 Financial Results
- Nov 13th, 2024 12:00 pm
Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients
- Sep 30th, 2024 11:00 am
Leap Therapeutics Reports Second Quarter 2024 Financial Results
- Aug 12th, 2024 11:00 am
Leap Therapeutics Inc (LPTX) Q1 2024 Earnings: Financial Resilience Amidst Clinical Progress
- May 13th, 2024 12:31 pm
Leap Therapeutics Reports First Quarter 2024 Financial Results
- May 13th, 2024 11:00 am
Pipeline Moves: Investigator-led trial of Lilly’s merestinib in solid tumours terminated
- Apr 29th, 2024 8:01 am
Leap Therapeutics Announces $40 Million Private Placement
- Apr 11th, 2024 12:30 pm
Here's Why Leap Therapeutics (LPTX) is Poised for a Turnaround After Losing -28.92% in 4 Weeks
- Mar 20th, 2024 1:35 pm
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
- Mar 18th, 2024 11:00 am
Scroll